Important Safety Information
VYEPTI™ (eptinezumab-jjmr) is the first FDA-approved prescription infusion medication used to treat migraines in adults. In addition to providing relief from symptoms, it has been proven to prevent additional migraines. In clinical trials, VYEPTI™ reduced migraines in 75% of patients treated, and most of them were migraine-free for a month or more.
VYEPTI™ may cause allergic reactions in some individuals. Tell your healthcare provider immediately if you experience breathing difficulties, itching, hives, or swelling of your face, throat, lips, and/or tongue. In addition, discuss with your doctor all medications you’re currently taking — regardless of whether they’re prescription, over-the-counter, vitamins, or herbal supplements. Mixing medications could be harmful.
What is the most important information I should know about VYEPTI™?
During clinical trials, most allergic reactions occurred during the infusion. Therefore, all treatment sessions should be closely monitored by a healthcare professional.
Tell your doctor about your medical history. Do not undergo treatment with VYEPTI™ if you are allergic to eptinezumab or any of the medication’s ingredients. It is unknown if VYEPTI™ is safe in pediatric patients. It is also unknown whether the medication could harm a fetus or pass to a baby via breast milk. If you’re pregnant or planning on becoming pregnant, talk to your doctor about the risks and benefits of treatment.
Side Effects of VYEPTI™
As with any prescription medication, VYEPTI™ carries the risk of side effects. The most common ones include:
- Stuffy nose
- Sore throat
- Allergic reactions
Tell your doctor if you experience any negative side effects. You are also encouraged to report such side effects to the Food and Drug Administration (FDA) by visiting www.fda.gov/medwatch, or by calling 1-800-FDA-1088.
VYEPTI™ is used to treat migraines. Each infusion treatment is administered for 30 minutes, four times per year. Dosage may vary between 100 mg and 300 mg, depending on the patient.
Please refer to the full prescribing information.